Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses

Immunotherapies in tumors have attracted increasing attention. They play an important role in precision medicine. Many immune-checkpoint inhibitors (ICIs) have obtained FDA approval and show good performance in the clinic. Hyperprogressive disease (HPD) after ICIs was first described in November 201...

Full description

Bibliographic Details
Main Authors: Hongjing Zang, Jinwu Peng, Hongmei Zheng, Songqing Fan
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Oncology
Subjects:
ICIs
immunotherapy
HPD
PD-1
PD-L1
CTLA-4
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00515/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00515/full

Similar Items